Faculty & Research Interests


Jadwiga S. Najib B.S., Pharm.D.
Professor, Pharmacy Practice, LIU Pharmacy
Clinical Pharmacist, Departments of Pharmacy and Psychiatry, Mount Saini West
(212) 523-8226


B.S. Pharmacy - St. John’s University, Jamaica, NY
Pharm.D., University of Minnesota, Minneapolis, MN

Short Biography

Dr. Najib holds a B.S. in Pharmacy from St. John’s University, and her Pharm.D. from the University of Minnesota. Dr. Najib’s practice site is at Mt. Sinai West and she joined the faculty at LIU Pharmacy in 1989 as Assistant Professor and was promoted to Full Professor in 2008. In addition to teaching didactic classes she precepts pharmacy students and residents at the site.

Dr. Najib is the recipient of the David Newton Award for Excellence in Teaching from LIU and has received recognition from Marquis Who’s Who in America, Publications Board. She has presented and published research papers dealing with various psychiatric disorders. She has authored and co-authored chapters in several books with international experts on psychiatric disorders and legal experts dealing with drug liability and safety. Most recently her work has been referenced in the latest international consensus guidelines on evidence-based treatment of insomnia published by the British Association for Psychopharmacology. Dr. Najib is a reviewer for over a dozen medical and pharmacy journals and serves on the International Editorial Advisory Board for Current Medical Research and Opinion.

Dr. Najib has chaired or co-chaired various committees at the college and departmental levels at Long Island University. Since 2008 she has been appointed by the Commissioner to the New York State Department of Health Medicaid Drug Utilization Review (DUR) Board, where she serves as a Drug Utilization Review Expert and with the Board is responsible for the establishment and implementation of medical standards and criteria for the retrospective and prospective DUR programs as well as the development, selection, application, and assessment of educational interventions for physicians, pharmacists and recipients to improve patient care.

Research Synopsis

Stigma of mental illness is a major barrier to effective management of many mental health conditions. Pharmacists are a valuable resource in increasing public awareness about mental health conditions and services, and can address barriers by providing educational counseling sessions regarding medications used in managing various psychiatric disorders. Medication counseling improves adherence to medications and pharmacists can better serve their patients as they are frequently consulted for advice by both patients and other health care providers. Dr. Najib’s research interests include clinical management of attention-deficit-hyperactivity disorder, sleep disorders, mood disorders, including major depressive disorders, and bipolar disorders. Additionally, her research interests include drug-induced movement disorders and their management as well as legal implications. Her current interests include the social and behavioral aspects of public mental health.

Selected Publications

  • Najib JS, Bailey M. Drug-Induced Movement Disorders. In: O’Donnell, ed. Drug Injury: Liability, Analysis and Prevention. 4th ed. Tucson, AZ: Lawyers & Judges; (in press)
  • Najib JS. “Eszopiclone: Review and Clinical Applications in Chronic and Co-morbid Insomnia.” Chapter in Part II: Drugs to Treat Insomnia. Milestones in Drug Therapy Series. Drug Treatment of Sleep Disorders. Antonio Guglietta, ed. Springer International Publishing, Switzerland. 2015:159-189.
  • Rivkin A, Yin H, Borno L, Fabbio K, Kugler A, Maltz F, Marzella N, Mehta M, Najib J. “Revising Senior Pharmacy Grand Rounds to Incorporate Longitudinal Board Review to Prepare Students for Licensing Examination” Currents in Pharmacy Teaching and Learning. 2013:5(3):236-240. http://www.sciencedirect.com/science/article/pii/S1877129712001207
  • Najib JS. “Drug-Induced Movement Disorders”, Chapter 26 in: Drug Injury: Liability, Analysis and Prevention. 3rd ed. James T. O’Donnell, ed. Lawyers & Judges, Tucson, AZ, 2012:419-461.
  • Najib J. "Lisdexamfetamine in the Treatment of Adolescents and Children with Attention-Deficit/Hyperactivity Disorder", Adolescent Health, Medicine and Therapeutics. 2012;8(3):51–66. http://0-www.ncbi.nlm.nih.gov.liucat.lib.liu.edu/pubmed/24600287
  • Najib, JS. “Efficacy and Safety of Zopiclone and Eszopiclone in the Treatment of Primary and Comorbid Insomnia" Chapter in GABA and Sleep: Molecular, Functional and Clinical Aspects, Monti, Pandi-Perumal, Mohler eds., Springer Basel, Switzerland. 2010:413-452. http://link.springer.com/chapter/10.1007/978-3-0346-0226-6_18
  • Najib, J. “The Efficacy and Safety Profile of Lisdexamfetamine Dimesylate, a Prodrug of d-amphetamine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adults” Clinical Therapeutics 2009;31(1):142-176. http://0-www.ncbi.nlm.nih.gov.liucat.lib.liu.edu/pubmed/19243715
  • Najib J, Zammit G. “Eszopiclone: Efficacy and Safety”, Chapter 29 in Sleep Disorders: Diagnosis and Therapeutics, Pandi-Perumal SR, Verster J, Monti J, Lader M, Langer S, eds. Informa Healthcare UK Ltd. 2008: 324-351.
  • Najib JS. “Eszopiclone, a Nonbenzodiazepine Sedative-Hypnotic Agent for the Treatment of Transient and Chronic Insomnia”, Clinical Therapeutics 2006; 28(4):491-516. http://0-www.ncbi.nlm.nih.gov.liucat.lib.liu.edu/pubmed/16750462
    The above article was a cited reference during a consensus meeting held in London in May 2009 which led to publication of consensus insomnia guidelines by the British Association for Psychopharmacology (BAP), “the largest national organization of its kind worldwide…BAP started publishing consensus statements more than a decade ago, and the first BAP guidelines on depression were considered a landmark publication when they appeared in 1993.”
  • Wilson SJ et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010 Nov;24(11):1577-601. Available at: http://www.bap.org.uk/pdfs/BAP_Sleep_Guidelines.pdf
  • Najib JS. “Drug-Induced Movement Disorders”, Chapter 29 in Drug Injury: Liability, Analysis and Prevention. 2nd ed. James T. O’Donnell, ed. Lawyers & Judges, Tucson, AZ, 2005:489-516.
  • Najib JS. “Fenofibrate in the Treatment of Dyslipidemia: A Review of the Data as They Relate to the New Suprabioavailable Tablet Formulation”, Clinical Therapeutics 2002; 24(12):2022-2050. http://0-www.ncbi.nlm.nih.gov.liucat.lib.liu.edu/pubmed/12581543
  • Najib JS. “Entacapone: A Catechol-O-Methyltransferase Inhibitor for the Adjunctive Treatment of Parkinson’s Disease”, Clinical Therapeutics 2001; 23(6):802-832. http://0-www.ncbi.nlm.nih.gov.liucat.lib.liu.edu/pubmed/11440283
  • Najib JS. “Drug-Induced Movement Disorders”, Chapter 15 in Drug Injury: Liability, Analysis and Prevention. James T. O’Donnell, ed. Lawyers & Judges, Tucson, AZ, 2000:275-298.
  • Najib JS. "Tardive Dyskinesia: A Review and Current Treatment Options", American Journal of Therapeutics 1999; 61:51-60. http://0-www.ncbi.nlm.nih.gov.liucat.lib.liu.edu/pubmed/10423647


LIU Pharmacy
Arash T. Dabestani